Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Houman D Hemmati

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JAMA Ophthalmology|February 15, 2024
Is Recommending 0.01% Atropine for Myopia Control Clinically Meaningful?-ReplyKarla Zadnik, Ian Flitcroft, Houman D Hemmati
Seminars in Ophthalmology|November 21, 2012
Intraoperative wavefront aberrometry in cataract surgeryHouman D Hemmati, Daniel Gologorsky, Roberto Pineda
Immunotherapy|August 27, 2020
Immune checkpoint inhibitors and corneal transplant rejection: a call for awarenessHarpal Singh Sandhu, Houman D Hemmati, Reza Dana
No Shinkei Geka. Neurological Surgery|October 14, 2004
[Cancer stem cells in pediatric brain tumors]Ichiro Nakano, Houman D Hemmati, Harley I Kornblum
Journal of the American Chemical Society|March 6, 2012
Photoswitchable nanoparticles for triggered tissue penetration and drug deliveryRong Tong, Houman D Hemmati, Robert Langer, et al.
Investigative Ophthalmology & Visual Science|June 21, 2011
Relationship between outer retinal thickness substructures and visual acuity in eyes with dry age-related macular degenerationRajeev R Pappuru, Yanling Ouyang, Muneeswar Gupta Nittala, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2003
Cancerous stem cells can arise from pediatric brain tumorsHouman D Hemmati, Ichiro Nakano, Jorge A Lazareff, et al.
JAMA Ophthalmology|June 1, 2023
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical TrialKarla Zadnik, Erica Schulman, Ian Flitcroft, et al.
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|April 8, 2026
Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical TrialKarla Zadnik, Erica Schulman, Ian Flitcroft, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JAMA Ophthalmology|February 15, 2024
Is Recommending 0.01% Atropine for Myopia Control Clinically Meaningful?-ReplyKarla Zadnik, Ian Flitcroft, Houman D Hemmati
Seminars in Ophthalmology|November 21, 2012
Intraoperative wavefront aberrometry in cataract surgeryHouman D Hemmati, Daniel Gologorsky, Roberto Pineda
Immunotherapy|August 27, 2020
Immune checkpoint inhibitors and corneal transplant rejection: a call for awarenessHarpal Singh Sandhu, Houman D Hemmati, Reza Dana
No Shinkei Geka. Neurological Surgery|October 14, 2004
[Cancer stem cells in pediatric brain tumors]Ichiro Nakano, Houman D Hemmati, Harley I Kornblum
Journal of the American Chemical Society|March 6, 2012
Photoswitchable nanoparticles for triggered tissue penetration and drug deliveryRong Tong, Houman D Hemmati, Robert Langer, et al.
Investigative Ophthalmology & Visual Science|June 21, 2011
Relationship between outer retinal thickness substructures and visual acuity in eyes with dry age-related macular degenerationRajeev R Pappuru, Yanling Ouyang, Muneeswar Gupta Nittala, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2003
Cancerous stem cells can arise from pediatric brain tumorsHouman D Hemmati, Ichiro Nakano, Jorge A Lazareff, et al.
JAMA Ophthalmology|June 1, 2023
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical TrialKarla Zadnik, Erica Schulman, Ian Flitcroft, et al.
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|April 8, 2026
Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical TrialKarla Zadnik, Erica Schulman, Ian Flitcroft, et al.
Pageof 1